HER-2 tyrosine kinase pathway targets estrogen receptor and promotes hormone-independent growth in human breast cancer cells.
about
p27 phosphorylation by Src regulates inhibition of cyclin E-Cdk2Steroid-induced androgen receptor-oestradiol receptor beta-Src complex triggers prostate cancer cell proliferationTargeting the mammalian target of rapamycin (mTOR): a new approach to treating cancerAntiangiogenic Steroids in Human Cancer Therapy.Tyrosine kinase signalling in breast cancer: ErbB family receptor tyrosine kinasesNew targets for therapy in breast cancer: mammalian target of rapamycin (mTOR) antagonistsHER-2 overexpression differentially alters transforming growth factor-beta responses in luminal versus mesenchymal human breast cancer cellsTamoxifen Resistance: Emerging Molecular TargetsPhosphatidylinositol 3-kinase and antiestrogen resistance in breast cancerTargeting of erbB3 receptor to overcome resistance in cancer treatmentSerine 28 phosphorylation of NRIF3 confers its co-activator function for estrogen receptor-alpha transactivationPI3-kinase in concert with Src promotes the S-phase entry of oestradiol-stimulated MCF-7 cellsAn Experimental Analysis of the Molecular Effects of Trastuzumab (Herceptin) and Fulvestrant (Falsodex), as Single Agents or in Combination, on Human HR+/HER2+ Breast Cancer Cell Lines and Mouse Tumor XenograftsCytosolic phospholipase A2 activation correlates with HER2 overexpression and mediates estrogen-dependent breast cancer cell growth.Reduced androgen receptor expression accelerates the onset of ERBB2 induced breast tumors in female mice.Novel actions of estrogen to promote proliferation: integration of cytoplasmic and nuclear pathways.Human epidermal growth factor receptor-2 and estrogen receptor expression, a demonstration project using the residual tissue repository of the Surveillance, Epidemiology, and End Results (SEER) program.ERbeta in breast cancer--onlooker, passive player, or active protector?Cellular targets of estrogen signaling in regeneration of inner ear sensory epithelia.Integrative genome-wide expression analysis bears evidence of estrogen receptor-independent transcription in heregulin-stimulated MCF-7 cells.Genomics of signaling crosstalk of estrogen receptor alpha in breast cancer cells.Characterization of an engineered human purine nucleoside phosphorylase fused to an anti-her2/neu single chain Fv for use in ADEPTMinireview: Tipping the balance: ligand-independent activation of steroid receptors.Direct estrogen receptor (ER) / HER family crosstalk mediating sensitivity to lumretuzumab and pertuzumab in ER+ breast cancer.Artemin, a member of the glial cell line-derived neurotrophic factor family of ligands, is HER2-regulated and mediates acquired trastuzumab resistance by promoting cancer stem cell-like behavior in mammary carcinoma cells.Pathway-based analysis of breast cancer.EGFRvIII-induced estrogen-independence, tamoxifen-resistance phenotype correlates with PgR expression and modulation of apoptotic molecules in breast cancer.Oestrogen and growth factor cross-talk and endocrine insensitivity and acquired resistance in breast cancer.Rapid nitric oxide-mediated S-nitrosylation of estrogen receptor: regulation of estrogen-dependent gene transcriptionCyclin D1 is required for transformation by activated Neu and is induced through an E2F-dependent signaling pathway.Activation of the Src/p21ras/Erk pathway by progesterone receptor via cross-talk with estrogen receptor.Non-transcriptional action of oestradiol and progestin triggers DNA synthesis.Redefining hormone resistance in prostate cancer.GP88 (PC-Cell Derived Growth Factor, progranulin) stimulates proliferation and confers letrozole resistance to aromatase overexpressing breast cancer cellsFunction of RasGRP3 in the formation and progression of human breast cancerDifferences in the transcriptional response to fulvestrant and estrogen deprivation in ER-positive breast cancerTamoxifen resistance and Her2/neu expression in an aged, irradiated rat breast carcinoma model.Inducible expression of FGF-3 in mouse mammary gland.The role of HER2 in cancer therapy and targeted drug deliverySomatic expression of PyMT or activated ErbB2 induces estrogen-independent mammary tumorigenesis.
P2860
Q24294568-99B2B5E6-08E3-409A-B10C-A7D294ED07F2Q24631073-D377B4DF-A545-4BE7-A606-26816B1AC142Q24645461-E2EBF310-A831-415B-9F88-15DC73C40D19Q24795360-00AB3D1D-D662-43EA-8218-D437B8B4DAA2Q24802950-C904DE02-2A19-444E-98BF-5E6E30311789Q24806542-57094783-C78C-4C9D-AF1F-AD8D733C62EBQ25257668-CE221387-D1FA-4117-987D-F13EE090F5BFQ26739969-4F072D04-F0B6-4C48-B783-7CB5DD168D90Q26862550-BF207980-1D62-4080-B3CD-59DBCBE3B87EQ26864668-B7FBCB00-E6FA-40B5-A227-26918C6E140AQ28282462-4A795103-474A-4DCC-8F59-DB961C51E328Q28363087-57626052-2672-49EE-B7D8-D7B48173EFC9Q28468447-63A7BA25-B2E9-47D2-A572-8AE1F9709E26Q30352693-E62C2881-BE73-4C9A-9BE3-60302DAF7625Q30419961-4DDB78B9-A4A9-45A4-B670-677B3B7E603FQ30435726-B9EB17C2-2D2E-4387-8AF3-F0169EAFF7BBQ30437453-CCB9CAD1-8C2B-4342-AD7A-38102A5B6307Q30438399-89DD30BE-C334-4D80-B765-DA90830EE08CQ30478755-F6582835-4232-45F5-8BB3-B4FBB3BBF3C4Q33324386-9D8A3C19-EA7E-44B2-B5F3-C203E21B57A8Q33325484-332F3608-776C-424A-8921-CCC7F67ECF08Q33562665-AE77105C-6FC7-43A4-828B-8A2193740F24Q33631775-46EFA0EB-1DBD-4A26-B080-7EED39F26D6CQ33664216-5D705234-AF25-4907-BAB9-D92C0AB8908FQ33718457-D68014CC-61B3-492E-AA58-67E9CFAB5C75Q33758011-009C97CB-AE66-4525-B151-C3DF060E5AD3Q33793142-C26E6670-0F0D-47D5-8CAD-B404BA79EFCFQ33842800-5348770A-02F0-47F4-9A5D-093FE3E5550DQ33849982-CF8DD2B0-A557-43F0-8116-99A9547D61FFQ33884776-D5DAC2CA-EDBA-413F-A989-D59A13C9E3C2Q33888599-B70EBE1E-5984-46EA-8B7B-AD1D7D4B76BBQ33890864-C56CFC33-ED3E-4D5A-807F-BB0C55636024Q33903836-DCFF5A4C-7DCC-49B2-A167-1141AB52FE1BQ33928138-552959A7-5AA3-4419-AC90-C1F85F351CC1Q33960160-73BF59B2-97CC-466D-8ADE-756611439330Q33993400-75072574-6B6D-4948-92B5-BD0F960A8361Q34016364-BF28342D-91F7-434C-8604-32B2F0E7A596Q34037413-A9E25FEA-0027-49D4-923F-36DBACAC641CQ34054213-9CD2CA1C-D2C8-43F0-A46D-3962882262C1Q34105355-92281983-203C-4BC0-AC94-68C033E059B1
P2860
HER-2 tyrosine kinase pathway targets estrogen receptor and promotes hormone-independent growth in human breast cancer cells.
description
1995 nî lūn-bûn
@nan
1995年の論文
@ja
1995年学术文章
@wuu
1995年学术文章
@zh
1995年学术文章
@zh-cn
1995年学术文章
@zh-hans
1995年学术文章
@zh-my
1995年学术文章
@zh-sg
1995年學術文章
@yue
1995年學術文章
@zh-hant
name
HER-2 tyrosine kinase pathway ...... in human breast cancer cells.
@en
HER-2 tyrosine kinase pathway ...... in human breast cancer cells.
@nl
type
label
HER-2 tyrosine kinase pathway ...... in human breast cancer cells.
@en
HER-2 tyrosine kinase pathway ...... in human breast cancer cells.
@nl
prefLabel
HER-2 tyrosine kinase pathway ...... in human breast cancer cells.
@en
HER-2 tyrosine kinase pathway ...... in human breast cancer cells.
@nl
P2093
P1433
P1476
HER-2 tyrosine kinase pathway ...... h in human breast cancer cells
@en
P2093
Arboleda J
Pietras RJ
Sliwkowski MX
Wongvipat N
P304
P407
P577
1995-06-01T00:00:00Z